News for Adagene Inc. (ADAG)

Adagene (ADAG) has received positive feedback from the FDA for its clinical development plan involving muzastotug (ADG126) in combination with Merck's KEYT

- Alignment gained on Phase 2 inclusion/exclusion criteria, primary and secondary endpoints, and study design, including sample size and dosing regimen - Compa

Overview of FMR LLC (Trades, Portfolio)'s Recent Transaction On June 30, 2025, FMR LLC (Trades, Portfolio) executed a significant transaction involving Adagene

Adagene to provide proprietary antibody to ConjugateBio for development as novel bispecific ADCs

- Sanofi to exercise option on third SAFEbody discovery program and sponsor combination clinical trial with muzastotug

SAN DIEGO and SUZHOU, China, May 27, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (”œAdagene”) ( ADAG), a company transforming the discovery and development of no

Adagene Inc. (ADAG) will present at the Jefferies Global Healthcare Conference on June 5, 2025. Chief Strategy Officer Mickael Chane-Du will participate

On March 31, 2025, FIL Ltd (Trades, Portfolio), a prominent asset management firm, executed a significant transaction involving Adagene Inc, a China-based bioph

Adagene (ADAG) has made a strategic addition to its leadership team with the appointment of Dr. John Maraganore as Executive Advisor. Dr. Maraganore brings a we

SAN DIEGO and SUZHOU, China, April 23, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (”œAdagene”) ( ADAG), a company transforming the discovery and development of

Adagene (ADAG) to showcase updated clinical trial results at ASCO 2025. Focus on ADG126 in combination with Pembrolizumab for advanced MSS CRC treatment

SAN DIEGO and SUZHOU, China, April 07, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (”œAdagene”) ( ADAG), a company transforming the discovery and development of

Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial responses SAFEb

SAN DIEGO and SUZHOU, China, March 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (”œAdagene”) ( ADAG), a company transforming the discovery and development of

**media[559091]**

- Trial to begin enrolling in April; expected primary completion in mid-2027 - - Primary study endpoint of rate of major pathological response - SAN DIEGO

Transaction Overview On December 31, 2024, FIL Ltd (Trades, Portfolio), a renowned asset management firm, strategically increased its stake in Adagene Inc (ADAG

Muzastotug (ADG126), an Anti-CTLA-4 SAFEbody® in Combination with pembrolizumab showed 33% overall response rate in microsatellite stable colorectal cancer Fo

SAN DIEGO and SUZHOU, China, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (”œAdagene”) ( ADAG), a company transforming the discovery and development of n